VelcroVax: a bolt-on vaccine platform technology improves antibody titres against a viral glycoprotein in mice
Stonehouse, N. J.; Kingston, N. J.; Grehan, K.; Snowden, J. S.; Hassall, M.; Alzahrani, J.; Paesen, G. C.; Sherry, L.; Hayward, C. R.; Roe, A.; Stephen, S.; Tomlinson, D. C.; Zeltina, A.; Doores, K. J.; Ranson, N. A.; Stacey, M.; Page, M.; Rose, N. J.; Bowden, T. A.; Rowlands, D. J.
Show abstract
Having varied approaches to the design and manufacture of vaccines is critical in being able to respond to worldwide needs and to newly emerging pathogens. Virus-like particle (VLP) vaccines form the basis of two of the most successful licensed vaccines (against hepatitis B virus (HBV) and human papillomavirus). They are produced by recombinant expression of viral structural proteins, which self-assemble into immunogenic nanoparticles. VLPs can also be modified to present unrelated antigens, and here we describe a universal bolt-on vaccine platform (termed VelcroVax) where the capturing VLP and the target antigen (hapten) are produced separately. We utilise a modified HBV core (HBcAg) VLP, with surface expression of a high-affinity binding sequence (Affimer) directed against a SUMO tag and use this to capture SUMO-tagged gp1 glycoprotein from the arenavirus, Junin virus (JUNV). Using this model system, we have solved high-resolution structures of VelcroVax VLPs, and shown that the VelcroVax-JUNV gp1 complex induces superior humoral immune responses compared to the non-complexed viral protein. We propose that this system could be modified to present a range of haptens and therefore form the foundation of future rapid-response vaccination strategies.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Immunofocusing on the conserved fusion peptide of HIV envelope glycoprotein in rhesus macaques 96%
- Targeting HIV Env immunogens to B cell follicles in non-human primates through immune complex or protein nanoparticle formulations 96%
- Antibody elicited by HIV-1 immunogen vaccination in macaques displaces Env fusion peptide and destroys a neutralizing epitope 96%
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
Similar papers in this journal
- Protective Antibodies Against Human Parainfluenza Virus Type 3 (HPIV3) Infection 97%
- Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies 95%
- Nebulized delivery of a broadly neutralizing SARS-CoV-2 RBD-specific nanobody prevents clinical, virological and pathological disease in a Syrian hamster model of COVID-19 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.